Physician profile
Sohail Delfani
NPI 1568488740
$8,392.84
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,723 · 2020: $2,304 · 2021: $2,288 · 2022: $1,055 · 2023: $744 · 2024: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,162.64 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $923.31 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $814.07 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $567.93 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $550.39 | 2019-2022 | |
| Abbvie INC. | $404.74 | 2021-2023 | Ubrelvy |
| Pfizer INC. | $319.13 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.52 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $252.64 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $126.72 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $120.26 | 2022-2024 | |
| Amgen INC. | $118.47 | 2019-2022 | |
| Allergan, INC. | $117.62 | 2020 | |
| Currax Pharmaceuticals LLC | $113.57 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $99.91 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $88.24 | 2019-2021 | |
| Esperion Therapeutics, INC. | $79.00 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $73.86 | 2019-2020 | |
| Abbott Laboratories | $68.18 | 2022-2023 | Freestyle Libre 3 |
| Nalpropion Pharmaceuticals LLC | $66.01 | 2019 | |
| Phadia US INC. | $59.72 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.85 | 2019-2021 | |
| Amarin Pharma, INC. | $45.18 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $43.13 | 2024 | Horizant |
| Biohaven Pharmaceuticals, INC. | $41.49 | 2021 | |
| Eisai INC. | $40.80 | 2021 | |
| Horizon Therapeutics Plc | $40.17 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $29.32 | 2021 | |
| Axsome Therapeutics, INC. | $28.98 | 2024 | Sunosi |
| Ibsa Pharma INC. | $20.67 | 2024 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $17.19 | 2019 | |
| Valeritas, INC. | $15.00 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.18 | 2019 | |
| Vivus LLC | $11.97 | 2021 | |
| Corcept Therapeutics | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Delfani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.